10-QPeriod: Q3 FY2025

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q3 Ended Sep 30, 2025

Filed November 4, 2025For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. reported strong financial results for the third quarter and the first nine months of 2025, demonstrating significant year-over-year growth in product revenues. Total revenues reached $3.1 billion for the quarter, an 11% increase, and $8.8 billion for the nine-month period, up 9%, driven primarily by the sustained demand for their cystic fibrosis (CF) treatments, particularly TRIKAFTA/KAFTRIO, and early contributions from new product launches. The company also highlighted progress in expanding its therapeutic areas beyond CF, with notable advancements in its pipeline for sickle cell disease (SCD), beta-thalassemia (TDT), acute pain, and various kidney and autoimmune diseases. The acquisition of Alpine Immune Sciences in May 2024 continues to be a significant factor, contributing to R&D expenses but also bringing promising candidates like povetacicept into the pipeline. Despite increased operating costs, including R&D and SG&A expenses, driven by commercial investments and pipeline expansion, Vertex maintained robust profitability. The company ended the period with a healthy cash position of $12.0 billion, reflecting strong operating cash flow.

Financial Highlights

46 data points
Beta

Revenue

$3.08B

86.5% Gross Margin

Net Income

$1.08B

35.2% Net Margin

EPS (Diluted)

$4.20

Total Assets

$24.86B

Cash & Equivalents

$4.94B

Free Cash Flow

$1.14B

Financial Statements
Beta
Revenue$3.08B
Cost of Revenue$414.80M
Gross Profit$2.66B
SG&A Expenses$445.10M
Operating Expenses$1.89B
Operating Income$1.19B
Net Income$1.08B
EPS (Basic)$4.24
EPS (Diluted)$4.20
Shares Outstanding (Basic)255.60M
Shares Outstanding (Diluted)257.60M

Key Highlights

  • 1Product revenues increased by 11% year-over-year to $3.1 billion in Q3 2025, driven by strong demand for TRIKAFTA/KAFTRIO and new product contributions.
  • 2Total revenues grew 9% for the nine-month period ending September 30, 2025, reaching $8.8 billion.
  • 3Net income for the nine months was $2.8 billion, a significant turnaround from a net loss of $1.4 billion in the prior year period, largely due to a substantial acquired in-process R&D charge in 2024 related to the Alpine acquisition.
  • 4The company has a robust pipeline, with significant progress reported in clinical trials for its SCD/TDT therapies, Type 1 Diabetes programs, and kidney disease treatments.
  • 5Cash, cash equivalents, and marketable securities increased to $12.0 billion as of September 30, 2025, up from $11.2 billion at the end of 2024, supported by strong operating cash flows.
  • 6Vertex repurchased approximately $1.9 billion of its common stock in the first nine months of 2025 under its new $4.0 billion share repurchase program.

Frequently Asked Questions

The substantial increase in net income from a loss of $1.4 billion to a gain of $2.8 billion for the nine months ended September 30, 2025, is largely attributable to the absence of a significant $4.4 billion acquired in-process R&D expense in 2025, which was recognized in the nine months ended September 30, 2024, related to the acquisition of Alpine Immune Sciences, Inc. This year's results reflect strong revenue growth and operational efficiency.

Vertex is actively expanding its therapeutic reach. The company is advancing its pipeline in areas such as sickle cell disease and beta-thalassemia with CASGEVY, acute pain with JOURNAVX (which has seen over 300,000 prescriptions since March), and has promising candidates for IgA nephropathy, APOL1-mediated kidney disease, and Type 1 Diabetes. Partnerships and out-licensing agreements, such as those for povetacicept in Asian markets, also contribute to revenue diversification.

Royalty Pharma plc (RP), to whom the Cystic Fibrosis Foundation (CFF) assigned its rights, has initiated a confidential arbitration alleging that the royalty burden on ALYFTREK is approximately 8%, differing from Vertex's position of 4%. Vertex believes RP's claim is contrary to the CFF Agreement and intends to vigorously defend its position.

Vertex has a strong liquidity position with $12.0 billion in cash, cash equivalents, and marketable securities. The company recently authorized a $4.0 billion share repurchase program, with approximately $3.5 billion remaining as of September 30, 2025. This demonstrates confidence in future cash generation, which is expected to fund operations, R&D investments, potential milestone payments, and shareholder returns.